title: The next generation of novel therapies for the management of relapsed multiple myeloma.
abstract: The advent of various novel therapies such as immunomodulators and proteasome inhibitors has transformed the treatment paradigm for patients with multiple myeloma (MM). As a result, the overall survival has improved dramatically over the last decade. Despite these advances, MM remains mostly incurable and most patients experience disease relapse after enjoying a period of disease control or remission. Fortunately, the scientific community continues to make strides in developing 'next-generation' therapies for the management of patients with relapsed MM. This review will summarize the efficacy of some of the newest therapeutic agents available for the treatment of patients with relapsed MM after their upfront treatment with the original novel agents such as thalidomide, lenalidomide and bortezomib.
authors: The Divisions of Hematology & Blood & Marrow Transplantation, Mayo Clinic, Rochester, MN, USA.
authors: Wilson I
authors: WI
authors: Gonsalves
authors: Amyloidosis Research & Treatment Center, Department of Molecular Medicine, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo & University of Pavia, Pavia, Italy.
authors: Paolo
authors: P
authors: Milani
authors: Department of Hematology, Businco Hospital, Cagliari, Italy.
authors: Daniel
authors: D
authors: Derudas
authors: The Divisions of Hematology & Blood & Marrow Transplantation, Mayo Clinic, Rochester, MN, USA.
authors: Francis K
authors: FK
authors: Buadi
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D019468:Disease Management; D018450:Disease Progression; D006801:Humans; D058990:Molecular Targeted Therapy; D009101:Multiple Myeloma / Q000209:etiology / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents
keywords: multiple myeloma; novel agents; relapse